Tau transgenic mice as models for CSF tau biomarkers

Manuscript Number: 

11-0161R1

Author(s): 
Michael K. Ahlijanian, Charles F. Albright, Donna M. Barten, Gregory W. Cadelina, Lynn B. DeCarr, Marianne E. Flynn, Valerie L. Guss, Nina Hoque, Jere E. Meredith, Jr., Sethu Sankaranarayanan, Paul D. Wes, Ling Yang

Disclosures

Michael K. Ahlijanian

  • Equity:
    EnVivo Pharmaceuticals Bristol-Myers Squibb
    Sponsors:
    Bristol-Myers Squibb

Charles F. Albright

  • Equity:
    Bristol Myers Squibb
    Sponsors:
    Bristol Myers Squibb
    Patents/Royalties
    Brstol Myers Squibb

Donna M. Barten

  • Equity:
    Own stock and stock options in Bristol-Myers Squibb
    Sponsors:
    Employee of Bristol-Myers Squibb
    Patents/Royalties
    I have a patent application for work unrelated to this publication with Bristol-Myers Squibb

Gregory W. Cadelina

  • Sponsors:
    Bristol-Myers Squibb

Lynn B. DeCarr

  • Equity:
    I own BMS and Bayer AG stock
    Sponsors:
    I am employed by BMS
    Patents/Royalties
    I am an author on patents from Bayer AG

Marianne E. Flynn

  • Nothing to Disclose

Valerie L. Guss

  • Equity:
    Stock options Bristol-Myers Squibb Company
    Sponsors:
    Bristol-Myers Squibb Company

Nina Hoque

  • Nothing to Disclose

Jere E. Meredith, Jr.

  • Equity:
    I own stock in Bristol-Myers Squibb
    Sponsors:
    I am an employee of Bristol-Myers Squibb

Sethu Sankaranarayanan

  • Equity:
    Bristol-Myers Squibb
    Sponsors:
    Bristol-Myers Squibb

Paul D. Wes

  • Equity:
    Ownership of Bristol-Myers Squibb (BMS) stocks and restricted stock units.
    Sponsors:
    Bristol-Myers Squibb

Ling Yang

  • Nothing to Disclose